BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu CH, Liu CJ, Su TH, Fang YJ, Yang HC, Chen PJ, Chen DS, Kao JH. Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection. Open Forum Infect Dis 2017;4:ofx028. [PMID: 28480296 DOI: 10.1093/ofid/ofx028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int 2019;13:649-61. [PMID: 31541423 DOI: 10.1007/s12072-019-09988-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
2 Azeem HA, Alkabeer AM, Mohammed AS, Hussein AA. Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs). Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00121-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liu C, Su T, Liu C, Hong C, Yang H, Tseng T, Chen P, Chen D, Kao J. Sofosbuvir‐based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. Journal of Gastroenterology and Hepatology 2019;34:1620-5. [DOI: 10.1111/jgh.14615] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
4 Shahbaz O, Mahajan S, Lewis JH. Highlights of Drug - and Herb- induced liver injury in the Literature from 2016: How Best to Translate New Information into Clinical Practice? Expert Opin Drug Metab Toxicol. 2017;13:935-951. [PMID: 28772086 DOI: 10.1080/17425255.2017.1362391] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
5 Abdelbary MS, Samir R, El-nahaas SM, Hosny Shahin RM, El-sayed M, Gaber Y, Tantawi O, Zayed NA, Yosry A. Hepatitis B reactivation following eradication of HCV with direct-acting antiviral drugs (DAAs) in a cohort of patients from different institutions in Egypt. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.04.020] [Reference Citation Analysis]
6 El Kassas M, Shimakawa Y, Ali-Eldin Z, Funk AL, Wifi MN, Zaky S, El-Raey F, Esmat G, Fontanet A. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int 2018;38:2159-69. [PMID: 29738637 DOI: 10.1111/liv.13874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Liu CH, Shih YL, Yang SS, Lin CL, Fang YJ, Cheng PN, Chen CY, Peng CY, Hsieh TY, Chiu YC, Su TH, Liu CJ, Yang HC, Chen PJ, Chen DS, Kao JH. Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis. J Gastroenterol Hepatol 2019;34:1977-83. [PMID: 30931537 DOI: 10.1111/jgh.14672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
8 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol 2018;33:710-7. [PMID: 28762541 DOI: 10.1111/jgh.13912] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
9 Chen CH, Chen CH, Lin CL, Lin CY, Hu TH, Tung SY, Hsieh SY, Lu SN, Chien RN, Hung CH, Sheen IS. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep 2019;9:7086. [PMID: 31068655 DOI: 10.1038/s41598-019-43554-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
10 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018;13:e0209299. [PMID: 30576344 DOI: 10.1371/journal.pone.0209299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
11 Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep 2018;8:13699. [PMID: 30209349 DOI: 10.1038/s41598-018-32060-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
12 Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020;27:568-75. [PMID: 31981264 DOI: 10.1111/jvh.13265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver Int 2020;40:758-68. [PMID: 31710759 DOI: 10.1111/liv.14295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Liu CH, Chen CY, Su WW, Tseng KC, Lo CC, Liu CJ, Chen JJ, Peng CY, Shih YL, Yang SS, Huang CS, Huang KJ, Chang CY, Tsai MC, Kao WY, Fang YJ, Chen PY, Su PY, Tseng CW, Huang JJ, Lee PL, Lai HC, Hsieh TY, Chang CH, Huang YJ, Lee FJ, Chang CC, Kao JH. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut 2022;71:176-84. [PMID: 33408122 DOI: 10.1136/gutjnl-2020-323569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
16 Mak LY, Seto WK, Lai CL, Yuen MF. An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. Expert Opin Drug Metab Toxicol 2018;14:483-91. [PMID: 29718748 DOI: 10.1080/17425255.2018.1472236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Mücke MM, Mücke VT, Peiffer KH, Sarrazin C, Zeuzem S, Berger A, Vermehren J. Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study. Open Forum Infect Dis 2019;6:ofy340. [PMID: 30648130 DOI: 10.1093/ofid/ofy340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
18 Naderi N, Masoudi G, Behnava B, Alavian SM, Sari S, Anvar A, Azizi Saraji A, Namvar A, Bolhassani A. Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.83337] [Reference Citation Analysis]
19 El Kassas M, Eltabbakh M, Elbadry M, Tawheed A, Elbaz T. Establishing a research production line in real-life settings: the case of Hepatitis C management in a viral hepatitis specialized Egyptian center. Curr Med Res Opin 2022;:1-23. [PMID: 35118916 DOI: 10.1080/03007995.2022.2038489] [Reference Citation Analysis]
20 Liu CJ, Sheen IS, Chen CY, Chuang WL, Wang HY, Tseng KC, Chang TT, Yang J, Massetto B, Suri V, Camus G, Jiang D, Zhang F, Gaggar A, Hu TH, Hsu YC, Lo GH, Chu CJ, Chen JJ, Peng CY, Chien RN, Chen PJ. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up 108 Weeks Posttreatment. Clin Infect Dis 2021:ciab971. [PMID: 34864948 DOI: 10.1093/cid/ciab971] [Reference Citation Analysis]
21 Liu CJ, Chen PJ. Changing epidemiology of liver disease in Asia: Dual infection of HBV and HCV. Liver Int 2021. [PMID: 34402183 DOI: 10.1111/liv.15040] [Reference Citation Analysis]
22 Güçlü E, Alan S, Karabay O. Hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic Hepatitis C. Turk J Gastroenterol 2020;31:344-5. [PMID: 32412906 DOI: 10.5152/tjg.2020.18082] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Liu C, Shih YF, Liu CJ. Immunopathogenesis of Acute Flare of Chronic Hepatitis B: With Emphasis on the Role of Cytokines and Chemokines. Int J Mol Sci 2022;23:1407. [PMID: 35163330 DOI: 10.3390/ijms23031407] [Reference Citation Analysis]
24 Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. Ann Pharmacother 2019;53:294-310. [PMID: 30203666 DOI: 10.1177/1060028018800501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Chang JJ, Mohtashemi N, Bhattacharya D. Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era. Curr HIV/AIDS Rep 2018;15:172-81. [PMID: 29572624 DOI: 10.1007/s11904-018-0379-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
26 Pisaturo M, Macera M, Alessio L, Calò F, Coppola N. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses 2019;11:E850. [PMID: 31540223 DOI: 10.3390/v11090850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
27 Liu C, Liu C, Su T, Tseng T, Chen P, Kao J. Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13302] [Reference Citation Analysis]
28 Mücke MM, Backus LI, Mücke VT, Coppola N, Preda CM, Yeh M, Tang LSY, Belperio PS, Wilson EM, Yu M, Zeuzem S, Herrmann E, Vermehren J. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2018;3:172-80. [DOI: 10.1016/s2468-1253(18)30002-5] [Cited by in Crossref: 81] [Cited by in F6Publishing: 30] [Article Influence: 20.3] [Reference Citation Analysis]
29 Moretto F, Catherine FX, Esteve C, Blot M, Piroth L. Isolated Anti-HBc: Significance and Management. J Clin Med. 2020;9. [PMID: 31940817 DOI: 10.3390/jcm9010202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
30 Bello RO, Chin VK, Abd Rachman Isnadi MF, Abd Majid R, Atmadini Abdullah M, Lee TY, Amiruddin Zakaria Z, Hussain MK, Basir R. The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis. Int J Mol Sci 2018;19:E1149. [PMID: 29641433 DOI: 10.3390/ijms19041149] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
31 Poola S, Sanaka S, Sewell K, Tillmann HL. Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C. J Viral Hepat 2021;28:373-82. [PMID: 33047433 DOI: 10.1111/jvh.13421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Liu C, Kao J. Hepatitis C and hepatitis B coinfection. In: Foster GR, Reddy KR, editors. Clinical Dilemmas in Viral Liver Disease. Wiley; 2020. pp. 182-8. [DOI: 10.1002/9781119533481.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Preda CM, Popescu CP, Baicus C, Constantinescu I, Oproiu A, Voiosu T, Diculescu M, Negreanu L, Gheorghe L, Sporea I, Trifan A, Ceausu E, Proca D, Manuc M. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin. J Viral Hepat 2018;25:834-41. [PMID: 29397016 DOI: 10.1111/jvh.12872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Liu C, Lee M, Lin J, Liu C, Su T, Tseng T, Chen P, Chen D, Kao J. Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. Journal of Hepatology 2020;72:839-46. [DOI: 10.1016/j.jhep.2019.11.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
35 Liu CH, Sun HY, Liu CJ, Sheng WH, Hsieh SM, Lo YC, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther 2018;47:1690-8. [PMID: 29665069 DOI: 10.1111/apt.14647] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]